Expression of brain-specific angiogenesis inhibitor-1 and association with p53, microvessel density and vascular endothelial growth factor in the tissue of human bladder transitional cell carcinoma

Molecular Medicine Reports

Volumn 12, Issue 3, 2015, Pages 4522-4529

  Tian, Dawei ^a   Hu, Hailong ^a   Sun, Yan ^a   Tang, Yang ^a   Lei, Mingde ^a   Liu, Liwei ^a   Han, Ruifa ^a   Wu, Changli ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Bladder epithelial cells; Bladder urothelial carcinoma; Brain specific angiogenesis inhibitor 1; Vascular endothelium

Indexed keywords

BRAIN SPECIFIC ANGIOGENESIS INHIBITOR 1; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENIC PROTEIN; BAI1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGE; AGED; ARTICLE; BLADDER BIOPSY; BLADDER MUCOSA; BLADDER TRANSITIONAL CELL CARCINOMA; CANCER CELL; CAPILLARY DENSITY; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; FEMALE; GENDER; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OPTICAL DENSITY; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; WESTERN BLOTTING; BLADDER; BLADDER TUMOR; CANCER STAGING; CASE CONTROL STUDY; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROVASCULATURE; MIDDLE AGED; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENIC PROTEINS; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; CELL PROLIFERATION; DISEASE PROGRESSION; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84935433602     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3984     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
2. Rübben H, Lutzeyer W, Fischer N, Deutz F, Lagrange W and Giani G: Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139:283-285, 1988.
3. Sharifaghdas F and Beigi FM: Impalpable testis: laparoscopy or inguinal canal exploration? Scand J Urol Nephrol 42:154-157, 2008.
4. Reuter VE: The pathology of bladder cancer. Urology 67(Suppl 1):11-18, 2006.
5. Sylvester RJ, Van Der Meijden AP and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964-1970, 2002.
6. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124-1129, 2000.
7. Davis JW, Sheth SI, Doviak MJ and Schellhammer PF: Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167:494-501, 2002.
8. Nam DH, Park K, Suh YL and Kim JH: Expression of VEGF and brain specific angiogenesis inhibitor-1 in glioblastoma: prognostic significance. Oncol Rep 11:863-869, 2004.
9. Yoshida Y, Oshika Y, Fukushima Y, et al: Expression of angio-static factors in colorectal cancer. Int J Oncol 15:1221-1225, 1999.
10. Hatanaka H, Oshika Y, Abe Y, et al: Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angio-genesis inhibitor 1 (BAI1). Int J Mol Med 5:181-183, 2000.
11. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors (UICC). 6th edition. Wiley-Liss, New York, NY, pp199-203, 2002.
12. Kagan VE, Kisin ER, Kawai K, et al: Toward mechanism-based antioxidant interventions: lessons from natural antioxidants. Ann NY Acad Sci 959:188-198, 2002.
13. Kuwano M, Nakamura Y and Tokino T: A novel brain-specific p53-target gene, BAI1, containing thrombospondin type-1 repeats inhibits experimental angiogenesis. Oncogene 15:2145-2150, 1997.
14. Kim E and Deppert W: The versatile interactions of p53 with DNA: when fexibility serves specificity. Cell Death Differ 13:885-889, 2006.
15. Piaton E, Faýnel J, Ruffon A, Lopez JG, Perrin P and Devonec M: p53 immunodetection of liquid based processed urinary samples helps to identify bladder tumours with a higher risk of progression. Br J Cancer 93:242-247, 2005.
16. Wei M, Wanibuchi H, Morimura K, et al: Carcinogenicity of dimethylarsinic acid in male F334 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 23:1387-1397, 2002.
17. Anderson JC, McFarland BC and Gladson CL: New molecular targets in angiogenic vessels of glioblastoma tumours. Expert Rev Mol Med 10:e23, 2008.
18. Baenziger NL, Brodie GN and Majerus PW: A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA 68:240-243, 1971.
19. Naumov GN, Bender E, Zurakowski D, et al: A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316-325, 2006.
20. Okada K, Hirabayashi K, Imaizumi T, et al: Stromal thrombospondin-1 expression is a prognostic indicator and a new marker of invasiveness in intraductal papillary-mucinous neoplasm of the pancreas. Biomed Res 31:13-19, 2010.
21. Greenaway J, Lawler J, Moorehead R, Bornstein P, Lamarre J and Petrik J: Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1). J Cell Physiol 210:807-818, 2007.
22. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA and Bouck NP: CD36 mediates the in vitro inhibitory effects of throm-bospondin-1 on endothelial cells. J Cell Biol 138:707-717, 1997.
23. Dawson DW, Volpert OV, Pearce SF, et al: Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol 55:332-338, 1999.
24. Koh JT, Kook H, Kee HJ, et al: Extracellular fragment of brain-specific angiogenesis inhibitor 1 suppresses endothelial cell proliferation by blocking alphavbeta5 integrin. Exp Cell Res 294:172-18 4, 2004.
25. Nicosia RF: What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 153:11-16, 1998.
26. Kang SY and Watnick RS: Regulation of tumor dormancy as a function of tumor-mediated paracrine regulation of stromal Tsp-1 and VEGF expression. APMIS 116:638-647, 2008.
27. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990.
28. Elston CW and Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 41:154-161, 2002.
29. Kato T, Steers G, Campo L, et al: Prognostic significance of microvessel density and other variables in Japanese and British patients with primary invasive breast cancer. Br J Cancer 97:1277-1286, 2007.
30. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410, 2003.
31. El Moustaine D, Granier S, Doumazane E, et al: Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proc Natl Acad Sci USA 109:163 42-16347, 2012.
32. New DC and Wong YH: Molecular mechanisms mediating the G protein-coupled receptor regulation of cell cycle progression. J Mol Signal 2:2, 2007.